Intellia Therapeutics (NASDAQ:NTLA) Stock Price Expected to Rise, Chardan Capital Analyst Says

Intellia Therapeutics (NASDAQ:NTLA) had its target price raised by research analysts at Chardan Capital from $88.00 to $91.00 in a research report issued on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock.

A number of other research analysts also recently issued reports on NTLA. Oppenheimer decreased their price target on Intellia Therapeutics from $70.00 to $60.00 and set an “outperform” rating for the company in a report on Monday, November 11th. Stifel Nicolaus lowered their price target on shares of Intellia Therapeutics from $80.00 to $64.00 and set a “buy” rating on the stock in a report on Wednesday, September 11th. The Goldman Sachs Group cut their price objective on shares of Intellia Therapeutics from $31.00 to $20.00 and set a “neutral” rating for the company in a report on Friday, October 25th. Robert W. Baird lowered their target price on shares of Intellia Therapeutics from $24.00 to $18.00 and set a “neutral” rating on the stock in a research note on Friday, October 25th. Finally, Evercore ISI upgraded Intellia Therapeutics to a “strong-buy” rating in a research note on Friday, August 9th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $54.94.

Intellia Therapeutics Trading Down 0.3 %

Shares of NASDAQ:NTLA opened at $14.13 on Monday. Intellia Therapeutics has a twelve month low of $13.54 and a twelve month high of $34.87. The company has a market cap of $1.44 billion, a PE ratio of -2.60 and a beta of 1.81. The company’s 50 day moving average is $18.52 and its 200 day moving average is $21.97.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($1.34) EPS for the quarter, beating the consensus estimate of ($1.37) by $0.03. The business had revenue of $9.10 million during the quarter, compared to analysts’ expectations of $8.28 million. Intellia Therapeutics’s revenue for the quarter was down 24.1% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.38) earnings per share. Equities research analysts predict that Intellia Therapeutics will post -5.13 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CAO Michael P. Dube sold 2,012 shares of the business’s stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $19.01, for a total transaction of $38,248.12. Following the transaction, the chief accounting officer now owns 47,012 shares of the company’s stock, valued at approximately $893,698.12. The trade was a 4.10 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 3.20% of the company’s stock.

Hedge Funds Weigh In On Intellia Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Dimensional Fund Advisors LP lifted its holdings in Intellia Therapeutics by 8.1% in the second quarter. Dimensional Fund Advisors LP now owns 1,324,561 shares of the company’s stock valued at $29,648,000 after acquiring an additional 98,865 shares during the last quarter. Thrivent Financial for Lutherans purchased a new stake in Intellia Therapeutics in the second quarter valued at $679,000. American Century Companies Inc. grew its holdings in shares of Intellia Therapeutics by 23.8% during the 2nd quarter. American Century Companies Inc. now owns 330,514 shares of the company’s stock worth $7,397,000 after purchasing an additional 63,550 shares during the period. Comerica Bank grew its holdings in shares of Intellia Therapeutics by 853.6% during the 1st quarter. Comerica Bank now owns 37,105 shares of the company’s stock worth $1,021,000 after purchasing an additional 33,214 shares during the period. Finally, Vanguard Group Inc. increased its position in shares of Intellia Therapeutics by 8.9% during the 1st quarter. Vanguard Group Inc. now owns 9,093,712 shares of the company’s stock worth $250,168,000 after purchasing an additional 746,263 shares during the last quarter. 88.77% of the stock is currently owned by institutional investors and hedge funds.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.